Spero Therapeutics Stock Pattern Recognition Harami Pattern
| SPRO Stock | USD 2.58 -0.01 -0.39% |
| Symbol |
Recognition |
The output start index for this execution was eleven with a total number of output elements of fifty. The function generated a total of three valid pattern recognition events for the selected time horizon. The Harami pattern describes bullish reversal trend for Spero Therapeutics.
Spero Therapeutics Technical Analysis Modules
Most technical analysis of Spero Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Spero from various momentum indicators to cycle indicators. When you analyze Spero charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections and rare diseases in the United States. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. Spero Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. As a micro-cap equity, Spero Therapeutics is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/E of 81.2, P/B of 5.51, profit margin of -108.11%. Spero Therapeutics has a market cap of 145.92 M, P/E of 81.2, ROE of -95.3%.
Methodology
Unless otherwise specified, financial data for Spero Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Spero (USA Stocks:SPRO) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Spero Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Spero Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial BoardAlign your values with your investing style
Using Spero Therapeutics inside a theme workflow gives investors a structured way to compare related stocks, funds, ETFs, and crypto assets before allocating capital. The practical benefit is that the selected idea can be tuned either for higher upside or for tighter risk control.
Thematic Opportunities
Explore Investment Opportunities
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Disruptive Technologies Invested few shares | |
 | Momentum Invested over 20 shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Cash Cows Invested few shares | |
 | Blockchain Invested few shares | |
 | Advertising Invested few shares | |
 | Impulse Invested over 200 shares | |
 | Hedge Favorites Invested over 20 shares | |
More Resources for Spero Stock Analysis
Reviewing Spero Therapeutics commonly begins with financial statements and performance trends. Financial ratios provide context for profitability, efficiency, and growth trends. Selected reports below provide context for Spero Stock:Spero Therapeutics has a market cap of 145.92 M, operating margin of -134.68%, ROE of -95.3%. See World Market Map for portfolio-level analysis. This suggests a position in Spero Therapeutics within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. Our How to Buy Spero Stock guide explains the steps to invest in Spero Therapeutics stock.Analysis related to Spero Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Quarterly Earnings Growth 0.753 | Earnings Share -0.79 | Revenue Per Share | Quarterly Revenue Growth -0.60 | Return On Assets |
Investors evaluate Spero Therapeutics using market value and book value, each describing different facets of the business. Spero Therapeutics' market capitalization is 145.92 M. With a P/B ratio of 5.51, the market values Spero Therapeutics well above its book equity. Enterprise value stands at 100.65 M. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
The concept of value for Spero Therapeutics differs from its quoted price, since each reflects a different lens. For Spero Therapeutics, key inputs include a P/E ratio of 81.2, a P/B ratio of 5.51, a profit margin of -108.11%, and ROE of -95.3%. Trading price represents the transaction level agreed by market participants.